Evotec SE
Company Profile
Business description
Evotec is a drug discovery partnership firm providing solutions to pharmaceutical and biotechnology companies, academic institutions, foundations, and nonprofit organizations. The company offers services in a variety of therapeutic areas, including central nervous system disorders, diabetes, inflammation, oncology, infectious diseases, and women's health. The shared R&D segment, roughly 80% of sales, provides drug discovery and manufacturing services on a typical fee-for-service basis and integrated drug discovery collaborations based on its proprietary, internally developed assets. The Just-Evotec Biologics segment, about 20% of sales, offers CDMO services for biologics. As of 2023, the company has over 5,000 employees and 18 production sites mainly in Europe and the United States.
Contact
Essener Bogen 7
Manfred Eigen Campus
Hamburg22419
DEUT: +49 40560810
Sector
Healthcare
Stock type
Defensive
Industry
Drug Manufacturers - Specialty & Generic
Fiscal Year End
31 December 2026
Employees
4,766
Stocks News & Analysis
stocks
ASX listed gold miner under pressure due to lower production
stocks
3 ASX opportunities after earnings season
stocks
Oracle earnings: Solid execution secures revenue target and mitigates investor concerns
Morningstar Investment Ideas
Markets
Index | Last price | Change | % Change |
|---|---|---|---|
| All Ordinaries | 8,819.40 | 9.30 | -0.11% |
| CAC 40 | 8,000.36 | 64.39 | 0.81% |
| DAX 40 | 23,735.05 | 171.04 | 0.73% |
| Dow JONES (US) | 47,119.91 | 173.50 | 0.37% |
| FTSE 100 | 10,419.51 | 101.82 | 0.99% |
| HKSE | 25,868.54 | 34.52 | 0.13% |
| NASDAQ | 22,511.53 | 137.35 | 0.61% |
| Nikkei 225 | 53,700.39 | 50.76 | -0.09% |
| NZX 50 Index | 13,182.23 | 17.65 | 0.13% |
| S&P 500 | 6,734.92 | 35.54 | 0.53% |
| S&P/ASX 200 | 8,614.30 | 4.40 | -0.05% |
| SSE Composite Index | 4,049.91 | 34.88 | -0.85% |